Bruker Corp settles patent dispute with AbCellera
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Dec 25
Bruker Corp's stock rose by 5.05% as it crossed above the 20-day SMA, reflecting positive market conditions with the Nasdaq-100 up 0.37% and the S&P 500 up 0.65%.
This increase is attributed to Bruker Corp's settlement with AbCellera Biologics, where it will pay $36 million plus future royalties regarding a patent for microfluidic devices. Additionally, Wolfe upgraded Bruker to Outperform based on a positive outlook for 2026, which has contributed to investor confidence.
The settlement and upgrade signal a strong recovery potential for Bruker, suggesting that the company is well-positioned for growth in the coming years, especially with the anticipated improvements in end-market conditions.
Analyst Views on BRKR
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 46.550
Low
40.00
Averages
52.18
High
60.00
Current: 46.550
Low
40.00
Averages
52.18
High
60.00
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
